Merck announces ‘positive’ results from Phase 3 MK-3475A-D77 trial
Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be ...
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...
Medscape5h
When or Whether to Give Immunotherapy in Early Breast Cancer
Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...
Merck says injectable Keytruda succeeded in late-stage trial
Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the ...
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...